ZA201002090B - 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 - Google Patents

2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Info

Publication number
ZA201002090B
ZA201002090B ZA2010/02090A ZA201002090A ZA201002090B ZA 201002090 B ZA201002090 B ZA 201002090B ZA 2010/02090 A ZA2010/02090 A ZA 2010/02090A ZA 201002090 A ZA201002090 A ZA 201002090A ZA 201002090 B ZA201002090 B ZA 201002090B
Authority
ZA
South Africa
Prior art keywords
methylpyrrolidin
benzimidazole
crystalline form
carboxamide crystalline
carboxamide
Prior art date
Application number
ZA2010/02090A
Other languages
English (en)
Inventor
Lawrence Kolaczkowski
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201002090(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of ZA201002090B publication Critical patent/ZA201002090B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2010/02090A 2007-10-12 2010-03-24 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 ZA201002090B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12
PCT/US2008/079441 WO2009049111A1 (en) 2007-10-12 2008-10-10 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Publications (1)

Publication Number Publication Date
ZA201002090B true ZA201002090B (en) 2011-11-30

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/02090A ZA201002090B (en) 2007-10-12 2010-03-24 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Country Status (28)

Country Link
US (4) US8372987B2 (enExample)
EP (2) EP2212327A1 (enExample)
JP (4) JP2011500589A (enExample)
KR (2) KR20100090769A (enExample)
CN (2) CN101821270A (enExample)
AU (1) AU2008310781B2 (enExample)
BR (1) BRPI0816221A8 (enExample)
CA (2) CA3006332A1 (enExample)
CO (1) CO6280493A2 (enExample)
CR (1) CR11368A (enExample)
DK (1) DK2722046T3 (enExample)
DO (1) DOP2010000099A (enExample)
EC (1) ECSP10010150A (enExample)
ES (1) ES2620299T3 (enExample)
GT (1) GT201000080A (enExample)
MX (1) MX350019B (enExample)
MY (1) MY156691A (enExample)
NZ (1) NZ583209A (enExample)
PA (1) PA8798401A1 (enExample)
PH (1) PH12012501636A1 (enExample)
PL (1) PL2722046T3 (enExample)
PT (1) PT2722046T (enExample)
RU (2) RU2476434C2 (enExample)
SG (1) SG185297A1 (enExample)
TW (1) TWI422588B (enExample)
UA (2) UA101961C2 (enExample)
WO (1) WO2009049111A1 (enExample)
ZA (1) ZA201002090B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2212327A1 (en) 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
CN109071499A (zh) * 2016-03-09 2018-12-21 苏州晶云药物科技股份有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP2212327A1 (en) 2007-10-12 2010-08-04 Abbott Laboratories 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) * 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Also Published As

Publication number Publication date
CN105367554A (zh) 2016-03-02
DK2722046T3 (en) 2017-03-20
BRPI0816221A8 (pt) 2015-09-22
PT2722046T (pt) 2017-03-15
CR11368A (es) 2010-10-25
NZ583209A (en) 2012-06-29
US20150148392A1 (en) 2015-05-28
AU2008310781B2 (en) 2013-03-28
GT201000080A (es) 2012-04-03
TW200932747A (en) 2009-08-01
US20090099245A1 (en) 2009-04-16
CO6280493A2 (es) 2011-05-20
CA3006332A1 (en) 2009-04-16
EP2212327A1 (en) 2010-08-04
PH12012501636A1 (en) 2015-07-10
JP2011500589A (ja) 2011-01-06
US8372987B2 (en) 2013-02-12
PL2722046T3 (pl) 2017-06-30
MX2010003772A (es) 2010-04-21
SG185297A1 (en) 2012-11-29
AU2008310781A1 (en) 2009-04-16
MX350019B (es) 2016-12-09
EP2722046A1 (en) 2014-04-23
ECSP10010150A (es) 2010-06-29
CA2696424C (en) 2018-07-10
RU2476434C2 (ru) 2013-02-27
EP2722046B1 (en) 2016-12-21
PA8798401A1 (es) 2009-05-15
US8835647B2 (en) 2014-09-16
US20140024838A1 (en) 2014-01-23
KR20100090769A (ko) 2010-08-17
KR20160039312A (ko) 2016-04-08
MY156691A (en) 2016-03-15
US20130123317A1 (en) 2013-05-16
JP2017071618A (ja) 2017-04-13
UA113277C2 (xx) 2017-01-10
CA2696424A1 (en) 2009-04-16
TWI422588B (zh) 2014-01-11
UA101961C2 (xx) 2013-05-27
CN101821270A (zh) 2010-09-01
US9580410B2 (en) 2017-02-28
JP2019001811A (ja) 2019-01-10
ES2620299T3 (es) 2017-06-28
JP2014237659A (ja) 2014-12-18
DOP2010000099A (es) 2017-04-30
BRPI0816221A2 (pt) 2015-06-16
RU2010116397A (ru) 2011-11-20
WO2009049111A1 (en) 2009-04-16
RU2012147692A (ru) 2014-05-20

Similar Documents

Publication Publication Date Title
IL205513A0 (en) Novel compounds 132
IL205873A0 (en) Novel compounds 010
GB0713686D0 (en) New compounds 2
IL202050A0 (en) Herbicidally effective composition
ZA201000255B (en) Substituted bicyclolactam compounds
GB0704000D0 (en) Salts 670
IL199913A0 (en) Salts 668
IL212590A0 (en) New compounds 578
ZA201003909B (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
IL196722A0 (en) Crystalline antifungal compounds
GB0702459D0 (en) Salts 669
ZA200904423B (en) Crystalline forms GLYT 1
GB0808708D0 (en) New compounds 274
ZA200903614B (en) New crystalline forms
IL177762A0 (en) Bimatoprost crystalline form i
ZA201002213B (en) "6-pyrimidinyl-pyrimid-4-one derivative"
PT2722046T (pt) Forma cristalina 1 de 2-((r)-2-metilpirrolidina-2-yl)-1hbenzimidazol- 4-carboxamida
IL202281A0 (en) New compounds 892
GB0808707D0 (en) New compounds 275
PL2173710T3 (pl) Nowa postać krystaliczna
ZA200806859B (en) Novel crystalline compounds
GB0723342D0 (en) Novel compounds 2
HK1146282A (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
GB0723344D0 (en) Novel compounds 3
GB0713978D0 (en) New Compounds 4